Jennison Associates
CNTA

Jennison Associates’s Centessa Pharmaceuticals CNTA Stock Holding History

Jennison Associates’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-296,456
Closed -$4.95M – 667
2021
Q3 		$4.95M Sell
296,456
-3,544
-1% -$73.4K ﹤0.01% 484
2021
Q2 		$6.66M Buy
+300,000
New +$7.05M ﹤0.01% 484

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jennison Associates's CNTA Position: Q4 2021 in Review

Jennison Associates sold out of Centessa Pharmaceuticals (CNTA) in Q4 2021, closing a stake of 296,456 shares — an estimated $4.95M sold.

Jennison Associates first reported a position in CNTA in Q2 2021 and held it in 2 quarters. The position peaked at $6.66M in Q2 2021. 47 funds tracked by Wall St. Rank hold CNTA as of Q4 2021.

  • Jennison Associates reported no remaining Centessa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Jennison Associates sold 296,456 Centessa Pharmaceuticals shares in Q4 2021, an estimated $4.95M.
  • Jennison Associates first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Jennison Associates's Centessa Pharmaceuticals position peaked at $6.66M in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2021.

Based on Jennison Associates's 13F filing for Q4 2021, filed 8 Feb 2022.